Cidara Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Cidara Therapeutics Inc Unternehmen

Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Cidara Therapeutics Inc Informationen



BörsenkürzelCDTX

Name des UnternehmensCidara Therapeutics Inc

IPO-datumApr 15, 2015

CEODr. Jeffrey L. (Jeff) Stein, Ph.D.

Anzahl der mitarbeiter38

WertpapierartOrdinary Share

GeschäftsjahresendeApr 15

Addresse6310 Nancy Ridge Dr Ste 101

StadtSAN DIEGO

BörseNASDAQ Capital Market Consolidated

LandUnited States of America

Postleitzahl92121-3209

Telefon18587526170

Websitehttps://www.cidara.com/

BörsenkürzelCDTX

IPO-datumApr 15, 2015

CEODr. Jeffrey L. (Jeff) Stein, Ph.D.

Führungskräfte von Cidara Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Frank L. Karbe

Chief Financial Officer

57.50K

--

Mr. Daniel D. (Dan) Burgess

Independent Chairman of the Board

150.00

--

Mr. Ryan Spencer

Independent Director

--

Dr. Bonnie Bassler, Ph.D.

Independent Director

--

Ms. Chrysa Mineo

Independent Director

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

President, Chief Executive Officer, Director

--

Mr. Brian Ritchie

Investor Relations

--

Mr. Theodore R. (Ted) Schroeder

Independent Director

--

Mr. Shane Ward

Chief Operating Officer, Chief Legal Officer, Company Secretary

--

Dr. Josh Resnick, M.D., J.D.

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Frank L. Karbe

Chief Financial Officer

57.50K

--

Mr. Daniel D. (Dan) Burgess

Independent Chairman of the Board

150.00

--

Mr. Ryan Spencer

Independent Director

--

Dr. Bonnie Bassler, Ph.D.

Independent Director

--

Ms. Chrysa Mineo

Independent Director

--

Dr. Jeffrey L. (Jeff) Stein, Ph.D.

President, Chief Executive Officer, Director

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Fri, Oct 31

Aktionäre

Aktionärstypen

Aktionäre

Anteil

RA Capital Management, LP

10.70%

Bain Capital Life Sciences Investors, LLC

7.95%

Point72 Asset Management, L.P.

4.86%

Vivo Capital, LLC

4.17%

The Vanguard Group, Inc.

3.91%

Andere

68.40%

Aktionäre

Anteil

RA Capital Management, LP

10.70%

Bain Capital Life Sciences Investors, LLC

7.95%

Point72 Asset Management, L.P.

4.86%

Vivo Capital, LLC

4.17%

The Vanguard Group, Inc.

3.91%

Andere

68.40%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

40.25%

Investment Advisor

26.13%

Venture Capital

22.74%

Investment Advisor/Hedge Fund

18.53%

Research Firm

4.33%

Individual Investor

0.89%

Pension Fund

0.09%

Bank and Trust

0.08%

Private Equity

0.06%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

223

28.87M

92.92%

+14.12M

2025Q2

140

15.92M

78.58%

+7.99M

2025Q1

124

10.47M

53.54%

+2.71M

2024Q4

122

7.70M

70.35%

+1.07M

2024Q3

109

4.49M

61.04%

+771.77K

2024Q2

109

1.90M

39.70%

+56.88K

2024Q1

108

1.55M

384.06%

-209.94K

2023Q4

111

1.70M

37.69%

-299.58K

2023Q3

119

1.90M

42.77%

-451.34K

2023Q2

126

1.95M

43.98%

-451.51K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

RA Capital Management, LP

3.37M

13.27%

--

Aug 07, 2025

Bain Capital Life Sciences Investors, LLC

2.50M

9.86%

+1.80M

+255.68%

Jun 30, 2025

Point72 Asset Management, L.P.

1.53M

6.03%

+528.52K

+52.88%

Jun 30, 2025

Vivo Capital, LLC

1.31M

5.17%

+627.15K

+91.65%

Jun 30, 2025

The Vanguard Group, Inc.

966.71K

3.81%

+457.13K

+89.71%

Jun 30, 2025

BVF Partners L.P.

786.39K

3.1%

-138.25K

-14.95%

Jun 30, 2025

Commodore Capital LP

1.18M

4.63%

+1.18M

--

Jun 30, 2025

Paradigm BioCapital Advisors LP

1.13M

4.45%

+1.13M

--

Jul 23, 2025

Adage Capital Management, L.P.

1.10M

4.34%

+110.00K

+11.11%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.02M

4.03%

+974.57K

+2030.95%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Invesco Dorsey Wright Healthcare Momentum ETF

3.64%

Invesco Dorsey Wright SmallCap Momentum ETF

1.39%

SPDR S&P Biotech ETF

0.77%

Direxion Daily S&P Biotech Bull 3X Shares

0.41%

Even Herd Long Short ETF

0.39%

iShares Micro-Cap ETF

0.28%

VictoryShares US Small Mid Cap Value Momentum ETF

0.25%

Vanguard US Momentum Factor ETF

0.23%

iShares Russell 2000 Value ETF

0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.09%

Invesco Dorsey Wright Healthcare Momentum ETF

Anteil3.64%

Invesco Dorsey Wright SmallCap Momentum ETF

Anteil1.39%

SPDR S&P Biotech ETF

Anteil0.77%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.41%

Even Herd Long Short ETF

Anteil0.39%

iShares Micro-Cap ETF

Anteil0.28%

VictoryShares US Small Mid Cap Value Momentum ETF

Anteil0.25%

Vanguard US Momentum Factor ETF

Anteil0.23%

iShares Russell 2000 Value ETF

Anteil0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Anteil0.09%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Datum

Art

Verhältnis

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1

Apr 22, 2024

Merger

20→1